EUVIMEDEUVIMED entdecken
Crossref

Antiviral Therapy Reduces Dyslipidemia and Cardiovascular Risk in Chronic Hepatitis B: TDF as the Most Effective Agent

Hyuk Kim, Jae-Young Kim, Hyun Bin Choi, Ji-Soo Lee, Yoon E Shin, Jeong-Ju Yoo iD, Sang Gyune Kim, Young-Seok Kim

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70584 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Hyuk Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Gastroenterology and Hepatology, Soonchunhyang University Bucheon Hospital, Bucheon-si, Korea. Hauptthemen laut MEDLINE: Dyslipidemias, Antiviral Agents, Hepatitis B, Chronic, Cardiovascular Diseases. Die Arbeit nennt 26 Literaturangaben. Gefördert von: This study was supported by the Soonchunhyang University Research Fund (2025)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic hepatitis B (CHB) requires long‐term antiviral therapy, but its broader effects on metabolic and cardiovascular outcomes remain underexplored. This nationwide retrospective cohort study aimed to evaluate the impact of antiviral therapy on dyslipidemia and major adverse cardiovascular events (MACE) in CHB patients. Using the Korean Health Insurance Review and Assessment database, we identified 441 191 patients, of whom 48 606 received antiviral treatment and were matched 1:1 with untreated controls by propensity score. Antiviral therapy was associated with significantly lower incidence rates of both dyslipidemia (14.63 vs. 18.20 per 100 000 person‐years; IRR: 0.80, 95% CI: 0.76–0.85) and MACE (2.15 vs. 3.08 per 100 000 person‐years; IRR: 0.78, 95% CI: 0.67–0.91). Tenofovir disoproxil fumarate (TDF) showed the strongest protective effects against both outcomes, with adjusted hazard ratios of 0.52 for dyslipidemia and 0.58 for MACE. Stratified analysis revealed that the protective effects of antiviral therapy against dyslipidemia and MACE were primarily observed in nondiabetic patients, while only a nonsignificant trend toward risk reduction was noted in diabetic patients. These findings suggest that antiviral therapy, particularly TDF, provides extrahepatic benefits, supporting its role in the long‐term management of CHB beyond virologic suppression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DyslipidemiasAntiviral AgentsHepatitis B, ChronicCardiovascular DiseasesTenofovirHumansMaleFemaleRetrospective StudiesMiddle AgedAdultRepublic of KoreaAgedIncidence

Stichwörter der Autor:innen

antiviral agentsdyslipidemiahealth insurancemajor adverse cardiac events

Substanzen

Antiviral AgentsTenofovir

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Gastroenterology and Hepatology, Soonchunhyang University Bucheon Hospital, Bucheon-si, Korea.
  • Department of Internal Medicine, Soonchunhyang University School of Medicine, Bucheon-si, Korea.

ORCID-Profile: Jeong-Ju Yoo

Förderung

  • This study was supported by the Soonchunhyang University Research Fund (2025).

Zitieren

APA

Kim, H., Kim, J. Y., Choi, H. B., Lee, J. S., Shin, Y. E., Yoo, J. J., Kim, S. G., & Kim, Y. S. (2025). Antiviral Therapy Reduces Dyslipidemia and Cardiovascular Risk in Chronic Hepatitis B: TDF as the Most Effective Agent. Journal of Medical Virology. https://doi.org/10.1002/jmv.70584

Vancouver

Kim H, Kim JY, Choi HB, Lee JS, Shin YE, Yoo JJ, et al. Antiviral Therapy Reduces Dyslipidemia and Cardiovascular Risk in Chronic Hepatitis B: TDF as the Most Effective Agent. Journal of Medical Virology. 2025. doi:10.1002/jmv.70584

BibTeX
@article{Kim2025,
  author = {Kim, Hyuk and Kim, Jae-Young and Choi, Hyun Bin and Lee, Ji-Soo and Shin, Yoon E and Yoo, Jeong-Ju and Kim, Sang Gyune and Kim, Young-Seok},
  title = {Antiviral Therapy Reduces Dyslipidemia and Cardiovascular Risk in Chronic Hepatitis B: TDF as the Most Effective Agent},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70584}
}
Kostenlos starten →